Octagon Capital Advisors LP: DIANTHUS THERAPEUTICS IN (DNTH): Quarterly 13F Position History
As of Q1 2026, Octagon Capital Advisors LP reported 1,946,667 shares of DIANTHUS THERAPEUTICS IN (DNTH), worth $163.4M and representing 18.1% of its 13F equity book. Quarter-over-quarter share count change: 470,000 (-19.4%) . The position first appeared in Q3 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 1,946,667Shares Held (Latest Filing)
- $163.4MReported Market Value (Latest Filing)
- 18.1%Portfolio Weight (% of 13F Equity Book)
- 470,000Quarter-over-Quarter Share Change
- +$63.8MQuarter-over-Quarter Value Change
- 2,416,667Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,946,667 | 470,000 | -19.4% | $163.4M | 18.1% | $83.9 |
| Q4 2025 | 2,416,667 | 0 | — | $99.6M | 12.5% | $41.2 |
| Q3 2025 | 2,416,667 | +75,000 | +3.2% | $95.1M | 14.8% | $39.4 |
| Q2 2025 | 2,341,667 | +282,280 | +13.7% | $43.6M | 9.6% | $18.6 |
| Q1 2025 | 2,059,387 | 50,780 | -2.4% | $38.1M | 7.5% | $18.5 |
| Q4 2024 | 2,110,167 | +363,500 | +20.8% | $46.0M | 7.8% | $21.8 |
| Q3 2024 | 1,746,667 | 0 | — | $47.8M | 7.7% | $27.4 |
| Q2 2024 | 1,746,667 | +366,000 | +26.5% | $45.2M | 7.5% | $25.9 |
| Q1 2024 | 1,380,667 | +826,667 | +149.2% | $41.4M | 5.0% | $30.0 |
| Q4 2023 | 554,000 | +74,000 | +15.4% | $5.8M | 0.9% | $10.4 |
| Q3 2023 | 480,000 | — | — | $6.6M | 1.2% | $13.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Octagon Capital Advisors LP first disclose a DNTH position in 13F-HR filings?
Octagon Capital Advisors LP first reported DIANTHUS THERAPEUTICS IN (DNTH) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Octagon Capital Advisors LP's most recent quarter-over-quarter share-count change in DNTH?
Between Q4 2025 and Q1 2026, Octagon Capital Advisors LP reduced its DNTH position by 470,000 shares (-19.4%), leaving 1,946,667 shares at a market value of $163.4M.
Does the implied price-per-share represent Octagon Capital Advisors LP's cost basis in DNTH?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.